Posted by Alan on March 13, 2002, at 8:54:07
In reply to Re: DR's UNDER THE INFLUENCE - GREAT ARTICLE!!! » Alan, posted by TSA West on March 13, 2002, at 0:17:52
> Drugs like BuSpar (buspirone) and Aurorix (moclobemide) have a lousy reputation among doctors, despite drug companies' investing years and big money in trying to sell them. Result: BuSpar becomes generic this year and will sell for next to nothing; Aurorix will never make it to the U.S. market.
___________________________________________I guess the sad fact is that all of that time and money "hyping" these drugs could have gone into R & D or into how to properly use these drugs in the first place. Sad but true.
In the case of ssri's, the marketing strategy has been at the expense of patients because these drugs are marketed mostly to non specialists that don't have the training or experience to dx and tease out mixed anx/depress (a catch all) and are prime targets for these Co.'s to take advantage of their inability to dx properly in order to see whether a BZD for instance would be more appropriate in the cases of primary anxiety with secondary depression as a result of the anxiety for example (this was my case). This puts the patient through months and years of ssri trials with minimal or mostly ineffectual results and all of the terrible side effects followed by augmentation with drugs to treat side effects with the patient ultimately being termed "unresponsive" or "atypical" while all along not having given the option of other drugs on an equal footing. It takes away the patient's (and many times the doctor's) freedom of choice.
But of course, BZD's are off brand now. Tell one something?
Alan
poster:Alan
thread:97720
URL: http://www.dr-bob.org/babble/20020313/msgs/97769.html